Skip to main content
. Author manuscript; available in PMC: 2018 Nov 1.
Published in final edited form as: J Thorac Oncol. 2017 Jun 10;12(11):e175–e177. doi: 10.1016/j.jtho.2017.06.002

Figure 3. Progression-free and overall survival of patients with ALK-rearranged lung cancers after initiation of crizotinib.

Figure 3

A. Progression-free survival (PFS) curve with median and yearly estimates. B. Overall survival (OS) curve with median and yearly estimates. Data was collected and managed using the REDCap electronic data capture at our institution. Tumor genotype was performed using the ALK fluorescence in situ hybridization (FISH) break-apart probe in diagnostic tumor samples. Response evaluation criteria in solid tumors was utilized when reviewing target/non-target radiographic images. PFS and OS were calculated in months (rounded to the nearest full month) from time of initiation of crizotinib. PFS and OS were explored using the Kaplan–Meier method. Statistical analyses and curves were obtained with the GraphPad Prism 6 software (GraphPad Software, La Jolla, CA).